E. Mittendorf

Monitoring circulating tumor cells in cancer vaccine trials

A. Stojadinovic, E. Mittendorf, G. Peoples, 2008, Human vaccines.

Early results of a phase I clinical trial of an Ii-Key/Her2/neu MHC class II peptide-based vaccine in breast cancer patients.

J. Murray, C. Shriver, G. Peoples, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Therapeutic cancer vaccines revamping: technology advancements and pitfalls

G. Curigliano, P. Romero, M. Disis, 2021, Annals of Oncology.

Peptide Vaccine Strategies in the Treatment of Cancer

E. Mittendorf, G. Peoples, G. Clifton, 2013 .

Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.

C. Perou, L. Carey, A. Wolff, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

LBA1 Final analysis of the placebo-controlled randomised phase III IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo) plus chemotherapy (CT) followed by open-label adjuvant atezo in patients (pts) with early-stage triple-negative breast cancer (eTNBC)

Tong Xu, L. Molinero, K. Punie, 2023, ESMO Open.